The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive Akt inhibitor GDC-0068.
J. Tabernero
Consultant or Advisory Role - Genentech
C. Saura
No relevant relationships to disclose
D. Roda Perez
No relevant relationships to disclose
R. Dienstmann
No relevant relationships to disclose
S. Rosello
No relevant relationships to disclose
L. Prudkin
No relevant relationships to disclose
J. A. Perez-Fidalgo
No relevant relationships to disclose
B. GraƱa
No relevant relationships to disclose
C. Jones
Employment or Leadership Position - Genentech
L. Musib
Employment or Leadership Position - Genentech
Y. Yan
Employment or Leadership Position - Genentech
P. H. Patel
Employment or Leadership Position - Genentech
J. Baselga
Consultant or Advisory Role - Genentech (U)
A. Cervantes
Consultant or Advisory Role - Roche (U)
Honoraria - Roche
Other Remuneration - Roche